Hologic wins MedTech breakthrough award for AI mammography
Hologic has secured the prestigious MedTech Breakthrough Award for “Best New Imaging Technology Solution,” with its Genius AI Detection PRO mammography platform earning recognition amongst record-breaking international competition from leading medical technology innovators across more than 18 countries.
The independent market intelligence organisation MedTech Breakthrough selected Hologic’s AI-driven breast cancer screening technology from thousands of nominations, highlighting the platform’s revolutionary impact on diagnostic accuracy and clinical workflow efficiency in mammographic interpretation.
Award recognises breakthrough diagnostic capabilities
The winning Genius AI Detection PRO system represents a significant advancement over Hologic’s flagship Genius AI Detection 2.0 Solution, incorporating sophisticated deep-learning algorithms trained on extensive mammography databases containing both benign cases and biopsy-proven malignancies.
The platform’s breakthrough lies in its intelligent risk stratification mechanism, which assigns suspicious findings numerical scores from 1 to 10, providing radiologists with granular lesion assessments, breast-specific evaluations, and comprehensive case-level diagnostics that transform interpretive precision.
“Receiving the MedTech Breakthrough Award for Genius AI Detection PRO is an honour and a testament to our team’s unwavering commitment to relentless innovation in women’s health,” said Mark Horvath, President of Breast and Skeletal Health Solutions.
Clinical validation demonstrates workflow transformation
The award-winning technology delivers measurable clinical impact through its intuitive red-yellow-green colour-coding system, where green cases indicate low cancer likelihood whilst red signals high suspicion. Validation studies demonstrate this visual framework reduces radiologists’ overall reading time by 24% whilst maintaining diagnostic excellence.
Enhanced specificity improvements result from the system’s integration of patients’ prior examinations into current analytical processes, creating longitudinal diagnostic perspectives that amplify detection accuracy for the 99% five-year survival rates achievable through early breast cancer identification.
- For more information, visit: https://www.hologic.com/hologic-products/breast-health-solutions/genius-ai-detection-technology
